Compare AZZ & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZZ | TVTX |
|---|---|---|
| Founded | 1956 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 2.8B |
| IPO Year | 1994 | 2013 |
| Metric | AZZ | TVTX |
|---|---|---|
| Price | $133.55 | $39.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $126.00 | $40.46 |
| AVG Volume (30 Days) | 131.5K | ★ 2.1M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 9.97 | N/A |
| Revenue | ★ $1,061,817,000.00 | N/A |
| Revenue This Year | $5.47 | $43.88 |
| Revenue Next Year | $6.13 | $33.16 |
| P/E Ratio | $13.44 | ★ N/A |
| Revenue Growth | ★ 14.53 | N/A |
| 52 Week Low | $74.00 | $13.88 |
| 52 Week High | $141.18 | $43.31 |
| Indicator | AZZ | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 67.44 |
| Support Level | $130.88 | $32.62 |
| Resistance Level | $141.18 | $41.44 |
| Average True Range (ATR) | 3.62 | 2.07 |
| MACD | 1.01 | 1.24 |
| Stochastic Oscillator | 65.84 | 74.92 |
AZZ Inc is a provider of galvanizing and a variety of metal coating solutions and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of Metal Coatings, Precoat Metals, and Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company generates the majority of its revenue from the United States.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.